Flublok Quadrivalent (Influenza Vaccine):
Proven to prevent more influenza in adults 50+1,2

In a randomized controlled trial, Flublok Quadrivalent provided 30% (95% CI: 10-47) better protection from influenza due to any PCRa-confirmed circulating strain versus a standard-dose quadrivalent inactivated influenza vaccine.1,2

Full efficacy data

SIMILAR SAFETY PROFILE

In 2 randomized controlled trials in adults 18‑49 and 50+ years of age, rates of injection site and systemic reactions were similar compared with a standard-dose quadrivalent inactivated influenza vaccine.1

a PCR = Polymerase chain reaction.

Full safety data

A UNIQUE VACCINE COMPOSITION:

3X MORE ANTIGEN

45 micrograms (mcg) of hemagglutinin (HA) per strain1 vs 15 mcg HA in a standard-dose influenza vaccine2

MADE WITH RECOMBINANT DNA TECHNOLOGY

  • This platform uses influenza genetic code to produce recombinant HA, which eliminates the need to grow influenza virus during manufacturing1
  • Unlike inactivated influenza virus, recombinant HA avoids antigenic adaptations or mutations that could lead to reduced vaccine effectiveness2

Indication

Flublok Quadrivalent is a vaccine indicated for active immunization against disease caused by influenza A subtype viruses and influenza type B viruses contained in the vaccine. Flublok Quadrivalent is approved for use in persons 18 years of age and older.

+

Study design

AIM OF STUDY1,2

In a phase 3-4, randomized, double-blind, active-controlled trial, the relative efficacy and safety of quadrivalent recombinant influenza vaccine (RIV4) vs a standard-dose, egg-grown quadrivalent inactivated influenza vaccine (IIV4) was assessed.

METHODS1,2

Key Inclusion Criteria

  • Adults 50 years of age or older
  • Living independently without clinically significant acute illness
  • Not receiving ongoing immunosuppressive therapy

Randomized

1:1
(N=~9000)

RIV4: Flublok Quadrivalent

  • Recombinant influenza vaccine
  • 45 mcg of HA per strain

IIV4: Fluarix® Quadrivalent (Influenza Vaccine)

  • Egg-grown, standard-dose inactivated influenza vaccine
  • 15 mcg of HA per strain

Primary Endpoint

  • RT-PCR–confirmed, protocol-defined influenza-like illness due to any influenza virus type or subtype

Select Secondary Endpoints

  • Culture-confirmed, protocol-defined influenza-like illness due to any influenza virus type or subtype
  • Local and systemic adverse reactions

In a randomized controlled trial, Flublok Quadrivalent was proven to prevent more influenza than a SD-QIV in adults 50+1,2

PRIMARY ENDPOINT1,2

30%

(95% CI: 10-47)

better protection against influenza

due to any PCR-confirmed strain

SECONDARY ENDPOINT1,2

43%

(95% CI: 21-59)

better protection against influenza

due to any culture-confirmed
circulating strain

In 2 separate studies, Flublok Quadrivalent exhibited a similar safety profile compared with a standard-dose quadrivalent inactivated influenza vaccine1

In the relative efficacy and safety trial of adults 50+, rates of local and systemic adverse reactions were similar (within 7 days of administration) among Flublok Quadrivalent and standard-dose quadrivalent inactivated influenza vaccine recipients.1

Adults 50+ Years of Age

Reaction, Any Grade

Fluarix Quadrivalent (Influenza Vaccine) (n=4,327)
Flublok Quadrivalent (n=4,312)

In an immunogenicity and safety trial in adults 18-49, rates of local and systemic adverse reactions were similar (within 7 days of administration) among Flublok Quadrivalent and standard-dose quadrivalent inactivated influenza vaccine recipients.1

Adults 18-49 Years of Age

Reaction, Any Grade

Fluarix Quadrivalent (Influenza Vaccine) (n=332)
Flublok Quadrivalent (n=996)

Recombinant DNA technology eliminates the need to grow influenza virus and avoids the possibility of mutation or adaptation2

Rotate your device to landscape mode or swipe to see more.

See how Flublok Quadrivalent is made

Watch the video to learn more.

To order Flublok Quadrivalent, call 1-800-VACCINE (1-800-822-2463) or click the button below.

Order Flublok QuadrivalentFlublok Quadrivalent (Influenza Vaccine)

Important Safety Information

Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine (including egg protein for Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent) or after previous dose of the respective vaccine. In addition, Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction after previous dose of any influenza vaccine.

Important Safety Information

Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine (including egg protein for Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent) or after previous dose of the respective vaccine. In addition, Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction after previous dose of any influenza vaccine.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should be based on careful consideration of the potential benefits and risks.

If Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent are administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be lower than expected.

Vaccination with Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent may not protect all recipients.

For Fluzone Quadrivalent, in children 6 months through 35 months of age, the most common injection-site reactions were pain or tenderness, erythema, and swelling; the most common solicited systemic adverse reactions were irritability, abnormal crying, malaise, drowsiness, appetite loss, myalgia, vomiting, and fever. In children 3 years through 8 years of age, the most common injection-site reactions were pain, erythema, and swelling; the most common solicited systemic adverse reactions were myalgia, malaise, and headache. In adults 18 years and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, headache, and malaise.

For Flublok Quadrivalent, in adults 18 through 49 years of age, the most common injection-site reactions were tenderness and pain; the most common solicited systemic adverse reactions were headache, fatigue, myalgia, and arthralgia. In adults 50 years of age and older, the most common injection-site reactions were tenderness and pain; the most common solicited systemic adverse reactions were headache, and fatigue.

For Fluzone High-Dose Quadrivalent, in adults 65 years of age and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, headache, and malaise.

For Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent, other adverse reactions may occur.

Before administration, please see the full Prescribing Information for Fluzone Quadrivalent, Flublok Quadrivalent, or Fluzone High-Dose Quadrivalent. Also, please see complete Patient Information for Fluzone Quadrivalent or Fluzone High-Dose Quadrivalent.

Fluzone Quadrivalent Influenza Vaccine logoFlublok Quadrivalent Influenza Vaccine logoFluzone High-Dose Quadrivalent Influenza Vaccine logo

References: 1. Flublok Quadrivalent [Prescribing Information]. Meriden, CT: Protein Sciences Corporation. 2. Dunkle LM, Izikson R, Patriarca P, et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Engl J Med. 2017;376:2427-2436.

MAT-US-2019705-v1.0-05/2021